title: Immunogenicity, safety and tolerability of meningococcal C CRM197 conjugate vaccine administered 3, 5 and 11 months post-natally to pre- and full-term infants.
abstract: A total of 79 pre-term infants with a gestational age > or =32 weeks and 74 full-term infants were studied in order to evaluate the immunogenicity, safety and tolerability of meningococcal C (MenC)-CRM(197) conjugate vaccine administered 3, 5 and 11 months post-natally. The evoked immune response seemed to be substantially similar in the pre- and full-term infants, and there were only clinically marginal differences in safety and tolerability between the groups. The results support the use of two doses of MenC-CRM(197) vaccine at 3 and 5 months of age for primary immunisation, with a booster dose being given at about 1 year. In addition to reducing costs, this scheme seems to assure global immunogenicity and potential efficacy that is better than that offered by the accelerated scheme of administration with only three doses of vaccine in the first months of life, and similar to that observed with a fourth dose used as booster after the first year.
authors.affiliation: Institute of Pediatrics, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via Commenda 9, 20122 Milan, Italy.
authors.forename: Susanna
authors.initials: S
authors.lastname: Esposito
authors.forename: Barbara
authors.initials: B
authors.lastname: Corbellini
authors.forename: Samantha
authors.initials: S
authors.lastname: Bosis
authors.forename: Lorenza
authors.initials: L
authors.lastname: Pugni
authors.forename: Elena
authors.initials: E
authors.lastname: Tremolati
authors.forename: Claudia
authors.initials: C
authors.lastname: Tagliabue
authors.forename: Daniela
authors.initials: D
authors.lastname: Toneatto
authors.forename: Fabio
authors.initials: F
authors.lastname: Mosca
authors.forename: Nicola
authors.initials: N
authors.lastname: Principi
mesh_terms: D000375:Aging / Q000276:immunology*; D000907:Antibodies, Bacterial / Q000032:analysis / Q000096:biosynthesis; D003363:Cost Control; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000032:analysis / Q000096:biosynthesis; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature / Q000276:immunology*; D008297:Male; D022401:Meningococcal Vaccines / Q000009:adverse effects / Q000191:economics / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000009:adverse effects / Q000191:economics / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate